|
| Authors | n (number of patients) | Conclusions and limitations |
|
| Montorsi et al. (1997) | 30 | Alprostadil injections led to superior rate of return of adequate erections;
no preoperative EF parameters, no questionnaire, small number of patients, short follow-up |
|
| Mulhall et al. (2005) | 132 | Pharmacologic penile rehabilitation protocol results in higher rates of
spontaneous erections and erectogenic drug response;
no placebo arm, strong patient selection bias, dropouts were not included |
|
| Montorsi et al. (2006) | 80 | No significant difference is IIEF scores of patients using on demand versus
daily PDE5 inhibitors post-NSRRP; compliance not reported |
|
| Bannowsky et al. (2008) | 43 | Daily low-dose sildenafil leads to improved recovery of EF post-NSRRP
(86% versus 66% placebo); small number of patients, not placebo-controlled,
single center, only included patients who showed preserved EF post-operative with
Rigiscan testing |
|
| Padma-Nathan et al. (2008) | 76 | First placebo-controlled trial suggesting benefit of daily PDE5 inhibitor use:
nightly sildenafil increased return of spontaneous erections; low percentage
(4%) considered responders in placebo arm, but strict definition of responders |
|
| McCullough et al. (2008) | 54 | Nightly sildenafil improved nocturnal erections versus placebo;
nocturnal tumescence data do not necessarily correlate with clinically
usable erections |
|
| Montorsi et al. (2008) | 628 | Nightly vardenafil did not have any effect beyond that of on demand use |
|